You just read:

Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 Selected for Oral Late-Breaker Presentation at UEG Week 2018

News provided by

Theravance Biopharma, Inc.

Oct 10, 2018, 08:30 ET